Neglected zoonoses and antimicrobial resistance : impact on one health and sustainable development goals /

Neglected Zoonoses and Antimicrobial Resistance: Impact on One Health and Sustainable Development Goals provides a thorough examination of how neglected zoonoses and antimicrobial resistance together hinder the achievement of sustainable development goals declared by the United Nations in the pursui...

Descripció completa

Guardat en:
Dades bibliogràfiques
Altres autors: Samanta, Indranil (Editor), Bandyopadhyay, Samiran (Editor), Sparagano, Olivier A. E. (Editor)
Format: Electrònic eBook
Idioma:anglès
Publicat: London ; San Diego, CA: Academic Press, an imprint of Elsevier, [2025]
Matèries:
Accés en línia:ScienceDirect
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
Taula de continguts:
  • Front Cover
  • NEGLECTED ZOONOSES AND ANTIMICROBIAL RESISTANCE
  • NEGLECTED ZOONOSES AND ANTIMICROBIAL RESISTANCE: IMPACT ON ONE HEALTH AND SUSTAINABLE DEVELOPMENT GOALS
  • Copyright
  • Dedication
  • Contents
  • Contributors
  • About the editors
  • Preface
  • 1
  • Sustainable Development Goal
  • 1. Sustainable Development Goals
  • 2. Origin of SDG: Transition from MDG
  • References
  • 2
  • Neglected zoonotic diseases
  • 1. Introduction
  • 1.1 Understanding neglected zoonotic diseases
  • 1.2 Impact and consequences
  • 2. Conclusion
  • References
  • 3
  • Neglected cystic and alveolar echinococcosis
  • 1. Public health relevance, risk factors, taxonomy, and genetic variation
  • 1.1 Public health relevance
  • 1.2 Risk factors
  • 1.3 Taxonomy and genetic variation
  • 2. Biology and ecology of E. multilocularis and E. granulosus s.l.
  • 2.1 Life cycles of Echinococcus granulosus sensu lato complex
  • 2.2 Life cycle of Echinococcus multilocularis
  • 2.3 Infectivity, pathogenicity, and parasite-host interactions
  • 3. Epidemiology of cystic and alveolar echinococcosis
  • 3.1 Global distribution of cystic echinococcosis
  • 3.2 Global distribution of alveolar echinococcosis
  • 4. Surveillance and control of cystic and alveolar echinococcosis
  • 4.1 Surveillance and control of cystic echinococcosis
  • 4.1.1 Targeted control programme for CE
  • 4.1.2 Focus on the control options for E. granulosus s.l.
  • 4.1.3 Focus on the surveillance options for E. granulosus s.l.
  • 4.1.4 Assumptions and ultimate goals for a successful CE control programme
  • 4.2 Surveillance and control options for alveolar echinococcosis
  • 4.2.1 Surveillance of E. multilocularis in foxes
  • 4.2.2 Control of E. multilocularis in foxes
  • 5. Diagnosis and clinical management of cystic and alveolar echinococcosis?
  • 5.1 Clinical features of human cystic and alveolar echinococcosis.
  • 5.2 Diagnosis of cystic and alveolar echinococcosis
  • 5.2.1 Laboratory diagnosis
  • 5.3 Clinical management of cystic and alveolar echinococcosis
  • References
  • 4
  • Cysticercosis: Matter of concern
  • 1. Mode of transmission
  • 2. Disease process
  • 3. Changeover of the traditional clinical symptoms into the current one/epidemiology
  • 4. Modern diagnostic techniques
  • 5. Treatment protocol
  • 6. Antiparasitic resistance
  • 7. Prevention and control strategy
  • 8. Vaccines used recently or under development
  • 9. Conclusion
  • References
  • 5
  • Zoonotic sleeping sickness (Trypanosoma brucei)
  • 1. Introduction
  • 2. Morphology and life cycle of Trypanosoma brucei
  • 3. Circadian disruption by sleeping sickness infection
  • 4. Infection and disease course
  • 5. Epidemiology, transmission, and risk factors
  • 6. Diagnosis
  • 7. Treatment and management
  • 8. In gambiense-HAT
  • 9. In rhodesiense-HAT
  • 10. Elimination strategies
  • 11. Vector control strategy
  • 12. Conclusion
  • References
  • 6
  • Leishmaniasis
  • 1. Introduction
  • 2. Etiology
  • 3. Distribution
  • 4. Host species and reservoirs
  • 5. Transmission and life cycle
  • 6. Pathogenesis
  • 7. Clinical features
  • 8. Diagnosis
  • 9. Treatment
  • 9.1 Pentavalent antimonials
  • 9.2 Amphotericin B
  • 9.3 Pentamidine
  • 9.4 Paromomycin
  • 9.5 Miltefosine
  • 9.6 Sitamaquine
  • 9.7 Immunotherapy
  • 10. Prevention and control
  • 10.1 Personal protection
  • 10.2 Chemical control
  • 10.3 Environmental modification
  • 10.4 Reservoir control
  • 10.5 Health education
  • 10.6 Vaccines
  • References
  • 7
  • Zoonotic tuberculosis
  • 1. Introduction
  • 2. Mycobacteria
  • 3. The importance of zoonotic tuberculosis
  • 4. Pathogenesis, clinical presentation, and pathology
  • 5. Diagnostic techniques
  • 6. Strategies of TB control and treatment
  • 7. Vaccines
  • 8. Conclusion remarks
  • References.
  • 8
  • Anthrax
  • 1. Epidemiological distribution
  • 2. Etiology
  • 3. Hosts
  • 4. Mode of transmission
  • 5. Disease process
  • 6. Changeover of the traditional clinical symptoms into the current one
  • 7. Economic importance
  • 8. Modern diagnostic techniques
  • 9. Treatment protocol
  • 10. Antibacterial resistance
  • 11. Prevention and control strategies
  • 12. Vaccines used recently or under development
  • 13. Conclusion
  • Acknowledgments
  • References
  • Further reading
  • 9
  • Brucellosis: A neglected zoonosis
  • 1. Introduction
  • 2. Etiology
  • 3. Brucella genome
  • 4. Distribution and population at risk
  • 5. Socioeconomic impact
  • 6. Hosts and mode of transmission
  • 7. Risk factors associated with transmission
  • 8. Diagnosis
  • 9. Control measures
  • 10. Conclusion
  • References
  • 10
  • Leptospirosis
  • 1. Introduction
  • 2. Etiology
  • 3. Host range
  • 4. Mode of transmission
  • 5. Disease process
  • 5.1 Leptospiral antigens and their role
  • 5.2 Adhesion to the cells and entry
  • 5.3 Virulence factors and the host's immune system's evasion
  • 5.4 Disease development
  • 6. Changeover of the traditional clinical symptoms into the current one
  • 6.1 In humans
  • 6.2 In animals
  • 6.2.1 Cattle
  • 6.2.2 Buffalo
  • 6.2.3 Sheep
  • 6.2.4 Goat
  • 6.2.5 Swine
  • 6.2.6 Horses and other pack animals
  • 6.2.7 Dog
  • 6.2.8 Cat
  • 7. Economic importance
  • 8. Treatment protocol
  • 8.1 In humans
  • 8.2 In animals
  • 9. Antibacterial resistance
  • 10. Prevention and control strategy
  • 11. Vaccines used recently or under development
  • 11.1 Bacterins
  • 11.2 Attenuated vaccines
  • 11.3 LPS-depleted vaccines
  • 11.4 Recombinant protein vaccines
  • 11.5 Recombinant subunit vaccine
  • 11.6 DNA vaccines
  • 12. Conclusion
  • References
  • 11
  • Relapsing fever borreliosis
  • 1. Introduction
  • 2. History
  • 3. Distribution
  • 3.1 Africa
  • 3.2 Asia and Eurasia.
  • 3.3 Europe
  • 3.4 The Americas
  • 4. Epidemiology
  • 4.1 Louse-borne relapsing fever
  • 4.2 Tick-borne relapsing fever
  • 5. Etiology
  • 6. Hosts
  • 6.1 Rodents
  • 6.2 Avians
  • 6.3 Bats
  • 6.4 Livestock and other animals
  • 7. Mode of transmission
  • 8. Disease process
  • 8.1 Vector-Borrelia interactions
  • 8.2 Host interactions
  • 9. Changeover of the clinical symptoms
  • 10. Economic importance
  • 11. Classical and modern diagnostic techniques
  • 11.1 Microscopical examination
  • 11.2 Serological methods
  • 11.3 In vitro cultivation
  • 11.4 Polymerase chain reaction
  • 11.5 LTT, MELISA, and ELISpot tests
  • 11.6 Luminex-based, Immuno-PCR techniques
  • 12. Treatment protocol and antibacterial resistance
  • 12.1 Louse-borne relapsing fever
  • 12.2 Tick-borne relapsing fever
  • 12.3 Additional considerations
  • 13. Prevention and control strategies
  • 13.1 Louse-borne RF
  • 13.2 Tick-borne RF
  • 14. Vaccines
  • References
  • 12
  • Rickettsioses
  • 1. Introduction
  • 2. Distribution and epidemiology
  • 3. Etiology
  • 4. Hosts
  • 5. Mode of transmission
  • 6. Pathogenesis
  • 7. Clinical manifestations
  • 7.1 Rickettsioses syndrome with a low probability of inoculation eschar
  • 7.2 Rickettsioses syndrome with a probability of inoculation eschar
  • 8. Economic importance
  • 9. Diagnosis
  • 10. Treatment
  • 10.1 Antibacterial resistance
  • 11. Prevention and control
  • 11.1 Vaccines used recently or under development
  • References
  • 13
  • Rabies
  • 1. Introduction
  • 2. Etiology
  • 3. Host
  • 4. Modes of transmission
  • 5. Disease process
  • 6. Incubation period
  • 7. Epidemiology
  • 8. Clinical manifestation of rabies
  • 9. Changeover of traditional clinical symptoms into current ones
  • 10. Economic importance of rabies
  • 11. Diagnosis
  • 12. Prevention and control strategy
  • 12.1 Prevention and control in animals.
  • 12.2 Prevention and control in humans
  • 13. Treatment protocol
  • 14. Vaccines used recently or under development
  • 14.1 Vaccines for use in domestic animals
  • 14.2 Vaccines for use in wild animals
  • 14.3 Vaccines for use in humans
  • 15. How rabies control is related to sustainable development goals?
  • 16. Some neglected but significant issues in rabies control
  • 16.1 Rabies in wildlife and its possible role in spillover to domestic animals and humans
  • 16.2 Role of waste management on stray dog population management and rabies control
  • 16.3 Influence of socioeconomic factors in the control of rabies
  • 16.4 Role of epidemiological modeling techniques in rabies prevention and control
  • 16.5 Lack of inclusion of PrEP in human immunization programs
  • 17. Conclusions
  • Acknowledgments
  • References
  • 14
  • Zoonotic antimicrobial resistance: Impact on human and animal health
  • 1. Definition
  • 2. Characteristics
  • 3. Correlation with neglected zoonotic diseases
  • 4. Impact on animal health
  • 5. Impact on human health
  • References
  • Further reading
  • 15
  • Dual obstacles to sustainable development goals
  • 1. How NZDs affect SDGs?
  • 2. What an antimicrobial resistance affects SDG?
  • References
  • 16
  • Mitigation strategy for neglected zoonotic diseases and antimicrobial resistance
  • 1. Introduction
  • 2. Mitigation strategies
  • 2.1 Food-borne-related NZDs
  • 2.2 Human and anthropogenic factors
  • 2.3 Environmental factors
  • 3. Antimicrobial resistance
  • 4. Conclusion
  • References
  • Index
  • Back Cover.